AstraZeneca plans to upgrade its listing on the New York Stock Exchange (NYSE) while maintaining its UK headquarters and presence on the London Stock Exchange. The aim of this transition is to provide better access for U.S. investors who cannot purchase American depositary receipts (ADRs), effectively aligning its NYSE listing with those in London and Stockholm.
This decision raises questions about the potential implications for other prominent UK-based companies, including Shell, BP, Unilever, and Diageo, many of which generate significant revenue in the U.S. It is possible that these firms might seek to follow suit, highlighting a trend where FTSE 100 companies maintain their UK listings while pursuing equal status in New York. This shift could lead to increased share trading activity in the U.S., where the investment base is more substantial and there is no 0.5% stamp duty on share transactions, unlike the UK system.
Importantly, AstraZeneca’s new listing arrangement allows UK buyers to circumvent stamp duty by settling trades under the U.S. system. If more companies adopt a similar approach, it could raise concerns for London’s capital markets and prompt a “mid-Atlantic drift.”
The recent announcement coincides with broader currents in globalization, particularly in capital markets, suggesting that while some aspects of globalization may be retracting, others remain robust. However, the lasting impact of AstraZeneca’s decision on London’s market attractiveness remains to be seen.
Regulatory and fiscal frameworks, particularly stamp duty, are being scrutinized amid these developments. There are calls for reassessing the UK’s financial transaction structures to enhance the domestic appeal of public markets. This would require a shift in focus towards fostering a vibrant ecosystem for UK equities as opposed to solely promoting private investment.
Source: https://www.theguardian.com/business/nils-pratley-on-finance/2025/sep/29/astrazenecas-listing-rejig-spells-long-term-danger-for-london